Ray Therapeutics Receives EMA PRIME Designation for RTx-015 Gene Therapy in Retinitis Pigmentosa
Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.